The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP

European Journal of Haematology

Volumn 69, Issue 5-6, 2002, Pages 265-274

  Jelkmann, Wolfgang ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Erythropoietin; Glycans; Glycoprotein metabolism; Pharmacokinetics; Recombinant protein

Indexed keywords

CARBOHYDRATE; GLYCOPROTEIN; IODINE 125; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; SIALIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANIMAL CELL; BINDING AFFINITY; CANCER PATIENT; CELL STRAIN BHK; CHO CELL; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; KIDNEY FAILURE; LIVER FUNCTION; NONHUMAN; NORMAL HUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; SITE DIRECTED MUTAGENESIS; THALASSEMIA;

BONE MARROW; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; ORGAN SPECIFICITY; RECEPTORS, ERYTHROPOIETIN;

EID: 0036865723     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.02813.x     Document Type: Review

References (111)

1. Jelkmann W. Use of recombinant human erythropoietin as an anti-anemic and performance enhancing drug. Curr Pharmaceut Biotechnol 2000;1:11-31.
2. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985;82:7580-7584.
3. Davis JM, Arakawa T, Strickland TW, Yphantis DA. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 1987;26:2633-2638.
4. Dordal MS, Wang FF, Goldwasser E. The role of carbohydrate in erythropoietin action. Endocrinology 1985;116:2293-2299.
5. Storring PL, Tiplady RJ, Gaines-Das RE, Rafferty B, Mistry YG. Lectin-binding assays for the isoforms of human erythropoietin: Comparison of urinary and four recombinant erythropoietins. J Endocrinol 1996;150:401-412.
6. Sasaki H, Bothner B, Dell A, Fukuda M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem 1987;262:12059-12076.
7. Imai N, Kawamura A, Higuchi M, et al. Physicochemical and biological comparison of recombinant human erythropoietin with human urinary erythropoietin. J Biochem (Tokyo) 1990;107:352-359.
8. Sasaki H, Ochi N, Dell A, Fukuda M. Site-specific glycosylation of human recombinant erythropoietin: Analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. Biochemistry 1988;27:8618-8626.
9. Hokke CH, Bergwerff AA, Van Deddem GW, Kamerling JP, Vliegenthart JF. Structural analysis of the sialylated N- and O-linked carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. Sialylation patterns and branch location of dimeric N-acetyllactosamine units. Eur J Biochem 1995;228:981-1008.
10. Rush RS, Derby PL, Smith DM, et al. Microheterogeneity of erythropoietin carbohydrate structure. Anal Chem 1995;67:1442-1452.
11. Rahbek-Nielsen H, Roepstorff P, Reischl H, Wozny M, Koll H, Haselbeck A. Glycopeptide profiling of human urinary erythropoietin by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom 1997;32:948-958.
12. Egrie JC, Grant JR, Gillies D, Aoki KH, Strickland TW. The role of carbohydrate on the biological activity of erythropoietin. Glycoconjugate J 1993;10:263 (Abstract).
13. Egrie JK, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84:3-10.
14. Abraham PA, St-Peter WL, Redic KK, Halstenson CE. Controversies in determination of epoetin (recombinant human erythropoietin) dosages. Clin Pharmacokinet 1992;22:409-415.
15. Zachee P. Controversies in selection of epoetin dosages. Issues Answers Drugs 1995;49:536-547.
16. MacDougall IC. Pharmacokinetics and pharmacodynamics of erythropoietin and darbepoetin alfa. In: Jelkmann, W, ed. Erythropoietin: Molecular Biology and Clinical Use. Johnson City: FP Graham Publishing, 2002: 319-330.
17. Jelkmann W. Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin (Rhepo). In: Nowrousian, MR, eds. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Vienna: Springer, 2002:203-221.
18. MacDougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989;1: 425-427.
19. Cotes PM, Pippard MJ, Reid CD, Winearls CG, OLIVER DO, Royston JP. Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. Q J Med 1989;70:113-137.
20. Salmonson T, Danielson BG, Wikström B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 1990;29:709-713.
21. Salmonson T, Danielson BG, Grahnen A, Wikstrom B. Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure. J Intern Med 1990;228:53-57.
22. McMahon FG, Vargas R, Ryan M, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990;76:1718-1722.
23. Flaharty KK, Caro J, Erslev A. et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 1990; 47:557-564.
24. Brockmöller J, Köchling J, Weber W, Looby M, Roots I, Neumayer H-H. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br J Clin Pharmacol 1992;34: 499-508.
25. Veng-Pedersen P, Widness JA, Pereira LM, Peters C, Schmidt RL, Lowe LS. Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J Pharm Sci 1995;84:760-767.
26. Lim VS, Degowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 1989;110:108-114.
27. Kindler J, Eckardt KU, Ehmers B, et al. Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrol Dial Transplant 1989;4:345-349.
28. Kampf D, Eckardt KU, Fischer HC, Schmalisch C, Ehmer B, Schostak M. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron 1992;61: 393-398.
29. Veng-Pedersen P, Widness JA, Pereira LM, Schmidt RL, Lowe LS. A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm Drug Dispos 1999;20:217-223.
30. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991;50:702-712.
31. Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. Pharmacokinetics and dose-response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Nephron 1991;59:399-402.
32. Storring PL, Tiplady RJ, Gaines DR, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998;100: 79-89.
33. Cheung WK, Natarajan J, Sanders M, Vercammen E. Comparative pharmacokinetics, safety, and tolerability after subcutaneous administration of recombinant human erythropoietin formulated with different stabilizers. Biopharm Drug Dispos 2000;21:211-219.
34. Acharya VN, Sinha DK, Almeida AF, Pathare AV. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis. J Assoc Physicians India 1995;43:539-542.
35. Bren A, Kandus A, Varl J, et al. A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: A prospective, controlled crossover study. Artif Organs 2002;26:91-97.
36. Sikole A, Spasovski G, Zafirov D, Polenakovic M. Epoetin omega for treatment of anemia in maintenance hemodialysis patients. Clin Nephrol 2002;57:237-245.
37. Tsuda E, Kawanishi G, Ueda M, Masuda S, Sasaki R. The role of carbohydrate in recombinant human erythropoietin. Eur J Biochem 1990;188:405-411.
38. Nimtz M, Martin W, Wray V, Kloppel KD, Augustin J, Conradt HS. Structures of sialylated oligosaccharides of human erythropoietin expressed in recombinant BHK-21 cells. Eur J Biochem 1993;213:39-56.
39. Nimtz M, Wray V, Rudiger A, Conradt HS. Identification and structural characterization of a mannose-6-phosphate containing oligomannosidic N-glycan from human erythropoietin secreted by recombinant BHK-21 cells. FEBS Lett 1995;365:203-208.
40. Goochee CF, Gramer MJ, Andersen DC, Bahr JB, Rasmussen JR. The oligosaccharides of glycoproteins: Bioprocess factors affecting oligosaccharide structure and their effect on glycoprotein properties. Bio-Technology (NY) 1991;9:1347-1355.
41. Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2002;98:3626-3634.
42. Jensen JD, Madsen JK, Jensen LW, Pedersen EB. Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. J Am Soc Nephrol 1994;5:177-185.
43. Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 1998;64:412-423.
44. Nielsen OJ. Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysls patients. Pharmacol Toxicol 1990;66:83-86.
45. Besarab A. Physiological and pharmacodynamic considerations for route of EPO adminstration. Semin Nephrol 2000;20:364-374.
46. Besarab A, Flaharty KK, Erslev AJ, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol 1992;2: 1405-1416.
47. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001;57: 411-418.
48. MacDougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000;20:375-381
49. Ibbotson T, Goa KL. Darbepoetin alfa. Drugs 2001;61:2097-2104.
50. Storring PL, Gaines DR. The International Standard for Recombinant DNA-derived Erythropoietin collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins. J Endocrinol 1992;134:459-484.
51. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60:741-747.
52. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-276.
53. MacDougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-2395.
54. Embury SH, Garcia JF, Mohandas N, Pennathur DR, Clark MR. Effects of oxygen inhalation on endogenous erythropoietin kinetics, erythropoiesis, and properties of blood cells in sickle-cell anemia. N Engl J Med 1984;311: 291-295.
55. Kinoshita H, Ohishi N, Kato M, Tokura S, Okazaki A. Comparative pharmacokinetics and distribution of human urinary erythropoietin and recombinant human erythropoietin in rats. Arzneim-Forsch 1991:41:1004-1007.
56. Tam RC, Coleman SL, Tiplady RJ, Storring PL, Cotes PM. Comparisons of human, rat and mouse erythropoietins by isoelectric focusing: Differences between serum and urinary erythropoietins. Br J Haematol 1991;79:504-511.
57. Durand G, Seta N. Protein glycosylation and diseases: Blood and urinary oligosaccharides as markers for diagnosis and therapeutic monitoring. Clin Chem 2000;46: 795-805.
58. Wide L, Bengtsson C. Molecular charge heterogeneity of human serum erythropoietin. Br J Haematol 1990;76:121-127.
59. Toyoda T, Arakawa T, Aoki K. Yamaguchi H. Stabilization of human recombinant erythropoietin through interactions with the highly branched N-glycans. J Biochem 2000;128:731-737.
60. Takeuchi M, Inoue N, Strickland TW, et al. Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. Proc Natl Acad Sci USA 1989;86:7819-7822.
61. Yamaguchi K, Akai K, Kawanishi G, Ueda M, Masuda S, Sasaki R. Effects of site-directed removal of N-glycosylation sites in human erythropoietin on its production and biological properties. J Biol Chem 1991;266:20434-20439.
62. Kawasaki N, Haishima Y, Ohta M, et al. Structural analysis of sulfated N-linked oligosaccarides in erythropoietin. Glycobiology 2001;11:1043-1049.
63. Fiete D, Srivastava V, Hindsgaul O, Baenziger JU. A hepatic reticuloendothelial cell receptor specific for SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha that mediates rapid clearance of lutropin. Cell 1991;67:1103-1110.
64. Fiete D, Beranek MC, Baenziger JU. The macrophage/endothelial cell mannose receptor cDNA encodes a protein that binds oligosaccharides terminating with SO4-4-GalNAcbetal,4GlcNAcbeta or Man at independent sites. Proc Natl Acad Sci USA 1997;94:11256-11261.
65. Takeuchi M, Takasaki S, Shimada M, Kobata A. Role of sugar chains in the in vitro biological activity of human erythropoietin produced in recombinant Chinese hamster ovary cell. J Biol Chem 1990;265:12127-12130.
66. Wasley LC, Timony G, Murtha P, et al. The importance of N- and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin. Blood 1991;77:2624-2632.
67. Delorme E, Lorenzini T, Giffin J, et al. Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 1992;31:9871-9876.
68. Hoglund M. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) - What is the difference? Med Oncol 1998;15: 229-233.
69. Goldwasser E, Kung CK, Eliason J. On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J Biol Chem 1974;249: 4202-4206.
70. Weikert S, Papac D, Briggs J, et al. Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nature Biotechnol 1999;17: 1116-1121.
71. Imai N, Higuchi M, Kawamura A, et al. Physicochemical and biological characterization of asialoerythropoietin. Suppressive effects of sialic acid in the expression of biological activity of human erythropoietin in vitro. Eur J Biochem 1990;194:457-462.
72. Lukowsky WA, Painter RH. Studies on the role of sialic acid in the physical and biological properties of erythropoietin. Can J Biochem 1972;50:909-917.
73. Fukuda MN, Sasaki H, Lopez L, Fukuda M. Survival of recombinant erythropoietin in the circulation: The role of carbohydrates. Blood 1989;73:84-89.
74. Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 1989; 73:90-99.
75. Dinkelaar RB, Engels EY, Hart AA, Schoemaker LP, Bosch E, Chamuleau RA. Metabolic studies on erythropoietin (EP). II. The role of liver and kidney in the metabolism of Ep. Exp Hematol 1981;9:796-803.
76. Lezon CE, Martinez MP, Conti MI, Bozzini CE. Plasma disappearance of exogenous erythropoietin in mice under different experimental conditions. Endocrine 1998; 8:331-333.
77. Widness JA, Veng-Pedersen P, Schmidt RL, Lowe LS, Kisthard JA, Peters C. In vivo 1251-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep. J Pharmacol Exp Ther 1996;279:1205-1210.
78. MacDougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 1991;20:99-113.
79. Coles GA, Liberek T, Davies ME, et al. Estimation of erythropoietin secretion rate in normal and uremic subjects. Am J Physiol 1992;263:F939-F944.
80. Emmanouel DS, Goldwasser E, Katz AI. Metabolism of pure human erythropoietin in the rat. Am J Physiol 1984;247:F168-F176.
81. Fu JS, Lertora JJ, Brookins J, Rice JC, Fisher JW. Pharmacokinetics of erythropoietin in intact and anephric dogs. J Labor Clin Med 1988;111:669-676.
82. Mladenovic J, Eschbach JW, Koup JR, Garcia JF, Adamson JW. Erythropoietin kinetics in normal and uremic sheep. J Labor Clin Med 1985;105:659-663.
83. Steinberg SE, Garcia JF, Matzke GR, Mladenovic J. Erythropoietin kinetics in rats, generation and clearance. Blood 1986;67:646-649.
84. Misaizu T, Matsuki S, Strickland TW, Takeuchi M, Kobata A, Takasaki S. Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin. Blood 1995;86:4097-4104.
85. Sytkowski AJ, Lunn ED, Davis KL, Feldman L, Siekman S. Human erythropoietin dimers with markedly enhanced in vivo activity. Proc Natl Acad Sci USA 1998;95:1184-1188.
86. Sytkowski AJ, Lunn ED, Risinger MA, Davis KL. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 1999;274:24773-24778.
87. Dalle B, Henri A, Rouyer-Fessard P, et al. Dimeric erythropoietin fusion protein with enhanced erythropoieric activity in vitro and in vivo. Blood 2001;97:3776-3782.
88. Stohlman F, Brecher G. Humoral regulation of erythropoiesis. V. Relationship of plasma erythropoietin level to bone marrow activity. Proc Natl Acad Sci USA 1959; 100:40-43.
89. Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati A, Beguin Y. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood 1998;91:2139-2145.
90. Jelkmann W, Wiedemann G. Serum erythropoietin level relationships to blood hemoglobin concentration and erythrocytic activity of the bone marrow. Klin Wochenschr 1990;68:403-407.
91. Yoon WH, Park SJ, Kim IC, Lee MG. Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats. Res Commun Mol Pathol Pharmacol 1997;96:227-240.
92. Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics. Exp Hematol 2001;29:425-431.
93. Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: Evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 2001;298:820-824.
94. Russell ES, Keighley G. The relation between erythropoiesis and plasma erythropoietin levels in normal and genetically anaemic mice during prolonged hypoxia or after whole-body irradiation. Br J Haematol 1972;22:437-452.
95. Bozzini CE. Influence of the erythroid activity of the bone marrow on the plasma disappearance of injected erythropoietin in dogs. Nature 1966;209:1140-1141.
96. Fried W, Gregory SA, Knospe WH, Trobaugh FE. Regulation of plasma erythropoietin levels in mice with impaired responsiveness to erythropoietin. J Laboratory Clin Med 1971;78:449-456.
97. Naets JP, Wittek M. Erythropoietic activity of marrow and disappearance rate of erythropoietin in the rat. Am J Physiol 1969;217:297-301.
98. Piroso E, Erslev AJ, Flaharty KK, Caro J. Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows. Am J Hematol 1991;36:105- 110.
99. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990;87:5978-5982.
100. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994;91:3974-3978.
101. Suzuki N, Ohneda O, Takahashi S, et al. Erythroidspecific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002; in press.
102. Clark R, Olson K, Fuh G, et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 1996;271:21969-21977.
103. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;14:469-475.
104. Pazur JH, Jensen PJ, Murray AK. Oligosaccharides as immunodeterminants of erythropoietin for two sets of anti-carbohydrate antibodies. J Protein Chem 2000;19: 631-635.
105. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313:806-810.
106. Broudy VC, Tait JF, Powell JS. Recombinant human erythropoietin, purification and analysis of carbohydrate linkage. Arch Biochem Biophys 1988;265:329-336.
107. Tsuda E, Goto M, Murakami A, et al. Comparative structural study of N-linked oligosaccharides of urinary and recombinant erythropoietins. Biochemistry 1988;27: 5646-5654.
108. Hayakawa T, Wada M, Mizuno K, Abe S, Miyashita M, Ueda M. In vivo biological activities of recombinant human erythropoietin analogues produced by CHO cells, BHK cells and C127 cells. Biologicals 1992;20:253-257.
109. Yang M, Butler M. Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms. Biotechnol Prog 2002;18:129-138.
110. Grabenhorst E, Schlenke P, Pohl S, Nimtz M, Conradt HS. Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells. Glycoconjugate J 1999;16:81-97.
111. Cointe D, Beliard R, Jorieux S, et al. Unusual N-glycosylation of a recombinant human erythropoietin expressed in a human lymphoblastoid cell line does not alter its biological properties. Glycobiology 2000;10:511-519.